> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kairos Pharma Glioblastoma Trial OK’d by FDA
- URL: https://www.fdaweb.com/kairos-pharma-glioblastoma-trial-okd-by-fda/
- Published: 2022-03-17T12:00:00.000Z
- Updated: 2026-09-14T17:36:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151387

FDA has given the green light to Kairos Pharma to begin a clinical trial of its activated T cell therapy (KROS 201) in patients with recurrent glioblastoma, a type of brain cancer. The Phase 1 trial will be conducted at Cedars Sinai Medical Center in Los Angeles.   

KROS 201 activated T cells (ATCs) are described as “killer T cells” which are developed in a cell culture by “activating a patient’s white blood cells with cytokines or T cell activating signals and by priming dendritic cells loaded with glioblastoma cancer stem cell specific antigens,” the company says. The potent activated T cells are infused intravenously into patients, it says, adding that the cells have been shown to kill cancer stem cells, the root cause of cancer.